Maria J. Medel-Pinto

Madrid, MD 28049, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices.

Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices.

Journal: Molecular biology reports
Published: December 27, 2022

Skin Phototype Could Be a Risk Factor for Multiple Sclerosis.

Skin Phototype Could Be a Risk Factor for Multiple Sclerosis.

Journal: Journal of clinical medicine
Published: May 11, 2020

Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

Journal: Journal of clinical medicine
Published: March 05, 2020

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.

Journal: Scientific reports
Published: February 12, 2020

Quality assessment on the long-term cryopreservation and nucleic acids extraction processes implemented in the andalusian public biobank.

Quality assessment on the long-term cryopreservation and nucleic acids extraction processes implemented in the andalusian public biobank.

Journal: Cell and tissue banking
Published: November 28, 2018

Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.

Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.

Journal: Clinica chimica acta; international journal of clinical chemistry
Published: August 23, 2018

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

Journal: Scientific reports
Published: August 08, 2017

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.

Journal: Scientific reports
Published: April 04, 2017

Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.

Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.

Journal: PloS one
Published: October 06, 2016

Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.

Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 11, 2016

Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis.

Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis.

Journal: British journal of pharmacology
Published: July 29, 2016

Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis.

Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis.

Journal: Neuropharmacology
Published: January 26, 2016
Showing 1-12 of 18

Last Updated: 09/26/2026